PART I . Overview CNS Pharmaceuticals, Inc. (CNS, the Company, we, us, or our) is a biotechnology company focused on developing innovative therapies for serious diseases in neurology and oncology. Together, these therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical spending, encompass some of the most prevalent and difficult to treat diseases affecting humanity, and are characterized by significant unmet medical need. Significant progress has been made in t...
Q2 FY2026 — expected 2026-07-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001683168-26-002550 | EDGAR | 43K words |
| 2025-03-31 | 2024-12-31 | 0001683168-25-002139 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0001683168-24-002032 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001683168-23-002086 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0001683168-22-001401 | EDGAR | — |
| 2021-02-12 | 2020-12-31 | 0001683168-21-000533 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001683168-20-000781 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001683168-25-008466 | EDGAR | 14K words |
| 2025-08-14 | 2025-06-30 | 0001683168-25-006162 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001683168-25-003733 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001683168-24-008125 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001683168-24-005711 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001683168-24-003531 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001683168-23-008144 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001683168-23-005609 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001683168-23-003311 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001683168-22-007532 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001683168-22-005637 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001683168-22-003588 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-11 | 0001683168-26-001664 | EDGAR | 1K words |
| 2026-03-02 | 0001683168-26-001413 | EDGAR | — |
| 2026-02-17 | 0001683168-26-001066 | EDGAR | — |
| 2025-12-17 | 0001683168-25-009208 | EDGAR | — |
| 2025-11-21 | 0001683168-25-008624 | EDGAR | — |
| 2025-07-22 | 0001683168-25-005284 | EDGAR | — |
| 2025-07-15 | 0001683168-25-005129 | EDGAR | — |
| 2025-05-15 | 0001683168-25-003575 | EDGAR | — |
| 2025-04-09 | 0001683168-25-002373 | EDGAR | — |
| 2025-03-31 | 0001683168-25-002140 | EDGAR | — |
168 total filings indexed. 139 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001729427 |
| Ticker | CNSP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.cnspharma.com |
| Listed | 2019-11-08 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report